Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX43 in advanced HCC
NCT06742892Phase 2Recruiting
- Sponsor
- Henlius
- Start
- Mar 2025
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HLX43 in hepatocellular carcinoma (HCC), sponsored by Henlius. Started Mar 2025; status: recruiting.
02
Drugs
HLX43
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06742892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06742892.